NCT03281577View on ClinicalTrials.gov

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

June 7, 2019

Study Completion Date

July 12, 2019

Conditions
Diabetic GastroparesisIdiopathic Gastroparesis
Interventions
DRUG

TAK-954

TAK-954 IV infusion.

DRUG

Placebo

TAK-954 placebo-matching IV infusion.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY